(17beta)-3-oxoandrost-4-en-17-yl acetate

• Product Name(17beta)-3-oxoandrost-4-en-17-yl acetate
  CAS No.1045-69-8
  Purity99%
  Min Quantity1Kilograms
  Price1~1
• View Contact Detail

• 
  Molecular Structure

Detailed Description

Striant and Testoderm, have patent expirations of August 23, 2019 and November 10, 2019, respectively. The National Institutes of Health states that approximately 5 million American men do not produce enough of the hormone testosterone. Axiron is a highly profitable testosterone replacement therapy, with a patent expiration of February 19, 2017. The testosterone replacement Axiron generated over $48 million dollars in profit in 2011.

Coined “The Wittert Study”, after Gary Wittert who is the leader of this study, this novel study is banking on being the first of many to address the worldwide epidemic of type 2 diabetes using testosterone treatment as a preventative. The International Diabetes Federation has stated that the cost to treat type 2 diabetes worldwide now hovers at 471 billion dollars.